|
|
||||||||
a Department of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;
b Division of Hematology/Oncology, University of Florida, Gainesville, Florida, USA
Key Words. Fas • FLIP • Caspase • Stem cells • CD34 • Progenitor cells • Apoptosis
Curt I. Civin, M.D., Johns Hopkins Oncology Center, Bunting-Blaustein Cancer Research Building, Room 2M44, 1650 Orleans Street, Baltimore, Maryland 21231, USA. Telephone: 410-955-8816; Fax: 410-955-8897; e-mail: civincu{at}jhmi.edu
We sought to determine whether lympho-hematopoietic stem-progenitor cells (HSC) from human placental/umbilical cord blood (CB) or adult mobilized blood (PBSC) are sensitive to Fas-induced apoptosis. Human CD34+ cells from CB or PBSC were cultured in serum-free medium, with or without hematopoietic growth factors (FKT: FLT-3 ligand [FL], KIT ligand [KL], and thrombopoietin [TPO]), and with or without soluble Fas ligand (sFasL) or agonistic anti-Fas antibody. After 5-48 hours of culture, cells were assessed for viability and stained with Annexin V and 7-Aminoactinomycin D for apoptosis analysis by fluorescence-activated cell sorting. Cultured cells were also assessed by in vitro hematopoietic colony-forming cell (CFC) and in vivo nonobese diabetic/severe combined immunodeficient mouse engraftment potential (SEP) assays. Levels of Fas, FLICE inhibitory protein (FLIP), and Caspase 8 mRNA in CD34+ cells were determined by real-time quantitative polymerase chain reaction. Expression of FLIP was confirmed by Western blotting. No decrease in viability, CFC, or SEP was observed in CB or PBSC CD34+ cells cultured in the presence of sFasL or agonistic anti-Fas antibody. Human CB and mobilized PBSC CD34+ cells expressed high levels of FLIP, low ratios of Caspase 8:FLIP, and low levels of Fas. Thus, human CB and PBSC CD34+ HSC were resistant to Fas pathway agonists. High-level expression of FLIP likely provides one level of protection of CD34+ cells from Fas-mediated apoptosis.
This article has been cited by other articles:
![]() |
F. Rezzoug, Y. Huang, M. K. Tanner, M. Wysoczynski, C. L. Schanie, P. M. Chilton, M. Z. Ratajczak, I. J. Fugier-Vivier, and S. T. Ildstad TNF-{alpha} Is Critical to Facilitate Hemopoietic Stem Cell Engraftment and Function J. Immunol., January 1, 2008; 180(1): 49 - 57. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pearl-Yafe, J. Stein, E. S. Yolcu, D. L. Farkas, H. Shirwan, I. Yaniv, and N. Askenasy Fas Transduces Dual Apoptotic and Trophic Signals in Hematopoietic Progenitors Stem Cells, December 1, 2007; 25(12): 3194 - 3203. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Askenasy, E. S. Yolcu, I. Yaniv, and H. Shirwan Induction of tolerance using Fas ligand: a double-edged immunomodulator Blood, February 15, 2005; 105(4): 1396 - 1404. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yada, N. Takamura, K. Inagaki-Ohara, M. K. O'Leary, C. Wasem, T. Brunner, D. R. Green, T. Lin, and M. J. Pinkoski The Role of p53 and Fas in a Model of Acute Murine Graft-versus-Host Disease J. Immunol., February 1, 2005; 174(3): 1291 - 1297. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Tiefenthaler, N Bacher, H Linert, O Muhlmann, S Hofer, N Sepp, A Amberger, F Geisen, G Obermoser, and G Konwalinka Apoptosis of CD34 cells after incubation with sera of leukopenic patients with systemic lupus erythematosus Lupus, June 1, 2003; 12(6): 471 - 478. [Abstract] [PDF] |
||||
![]() |
K. A. Whartenby, E. E. Straley, H. Kim, F. Racke, V. Tanavde, K. S. Gorski, L. Cheng, D. M. Pardoll, and C. I. Civin Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation Blood, October 16, 2002; 100(9): 3147 - 3154. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
